Table 1.

Characteristics of Participating Companies and Respondents (n = 20).

Respondent ID	Type of Products Company Produces	Size of Company	Does Company Use Structured Benefit–Risk Assessment?	Does Company have a Standard Operating Procedure for Structured Benefit–Risk Assessment?	Has Company used qBRA to Support Product Development?a
01	Biotechnology	Medium	Yes	Yes	No
02	Medical devices	Large	Yes	No	Yesa
03	Pharmaceuticals	Large	Yes	No	Yes
04	Pharmaceuticals	Large	Yes	Yes	Yes
05	Pharmaceuticals	Large	Yes	Yes	Yesa
06	Pharmaceuticals	Large	Yes	Yes	Yes
07	Pharmaceuticals	Large	Yes	Yes	Yes
08	Medical devices	Medium	Yes	Yes	Yes
09	Pharmaceuticals	Large	Yes	Yes	Yes
10	Biotechnology	Large	Yes	Yes	Yes
11	Pharmaceuticals	Large	Yes	Yes	No
12	Pharmaceuticals	Large	Yes	Yes	Yes
13	Pharmaceuticals	Large	Yes	No	Yes
14	Pharmaceuticals	Large	Yes	No	Yesa
15	Pharmaceuticals	Large	Yes	Yes	Yes
16	Medical devices	Large	No	No	Yes
17	Pharmaceuticals	Large	Yes	No	Yes
18	Pharmaceuticals	Large	No	No	No
19	Biotechnology	Medium	Yes	Yes	No
20	Pharmaceuticals	Medium	Yes	Yes	No

^aIn some instances, respondents responded to the direct question regarding whether their company had used qBRA by answering “no.” However, later in the survey, they indicated that one or more qBRA methods had been used in some capacity. In those instances, the original response was re-categorized as a “Yes*”